Collaboration Agreements (Tables)

3 Months Ended

Mar. 31, 2017

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Schedule of Revenues from Collaborations

The following table is a summary of the revenue recognized from the Company’s collaborations for the three months ended March 31, 2017 and 2016:

	Three Months Ended March 31,
	2017		2016
Teva:
Research funding	$	15	$	29
Genentech:
Recognition of upfront payment		—		157
Research funding		—		383
Total collaboration revenue	$	15	$	569